NO20082699L - Immunoglobuliner - Google Patents

Immunoglobuliner

Info

Publication number
NO20082699L
NO20082699L NO20082699A NO20082699A NO20082699L NO 20082699 L NO20082699 L NO 20082699L NO 20082699 A NO20082699 A NO 20082699A NO 20082699 A NO20082699 A NO 20082699A NO 20082699 L NO20082699 L NO 20082699L
Authority
NO
Norway
Prior art keywords
immunoglobulins
antibodies
disorders
nogo
prevention
Prior art date
Application number
NO20082699A
Other languages
English (en)
Norwegian (no)
Inventor
Jonathan Henry Ellis
Paul A Hamblin
Volker Germaschewski
Ruth Mcadam
Rabinder Kumar Prinjha
Stepanie Jane Clegg
George Kopsidas
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082699(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20082699L publication Critical patent/NO20082699L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20082699A 2005-12-16 2008-06-11 Immunoglobuliner NO20082699L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
PCT/EP2006/069737 WO2007068750A2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo

Publications (1)

Publication Number Publication Date
NO20082699L true NO20082699L (no) 2008-09-08

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082699A NO20082699L (no) 2005-12-16 2008-06-11 Immunoglobuliner

Country Status (31)

Country Link
US (2) US8362208B2 (uk)
EP (2) EP1960429B1 (uk)
JP (1) JP5015949B2 (uk)
KR (1) KR101355118B1 (uk)
CN (1) CN101374863B (uk)
AR (1) AR057239A1 (uk)
AU (1) AU2006325228B2 (uk)
BR (1) BRPI0619855A2 (uk)
CA (1) CA2633501C (uk)
CR (1) CR10099A (uk)
CY (1) CY1113094T1 (uk)
DK (1) DK1960429T3 (uk)
EA (1) EA015536B1 (uk)
ES (1) ES2389380T3 (uk)
GB (1) GB0525662D0 (uk)
HK (1) HK1119720A1 (uk)
HR (1) HRP20120684T1 (uk)
IL (1) IL192086A0 (uk)
JO (1) JO2795B1 (uk)
MA (1) MA30041B1 (uk)
MY (1) MY149492A (uk)
NO (1) NO20082699L (uk)
NZ (1) NZ569143A (uk)
PE (1) PE20071099A1 (uk)
PL (1) PL1960429T3 (uk)
PT (1) PT1960429E (uk)
SI (1) SI1960429T1 (uk)
TW (1) TWI378940B (uk)
UA (1) UA96279C2 (uk)
WO (1) WO2007068750A2 (uk)
ZA (2) ZA200805111B (uk)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
NZ584911A (en) * 2007-11-02 2011-08-26 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
TW201012489A (en) 2008-05-06 2010-04-01 Glaxo Group Ltd Encapsulation of biologically active agents
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
EP2870177A1 (en) 2012-07-05 2015-05-13 Glaxo Group Limited Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
AU2020370751A1 (en) 2019-10-24 2022-06-09 Novago Therapeutics Ag Novel anti-Nogo-A antibodies
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
MX2023015152A (es) 2021-06-17 2024-05-31 Petmedix Ltd Anticuerpos anti-cd20 canino.
WO2023067358A1 (en) 2021-10-21 2023-04-27 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
AU2023219227A1 (en) 2022-02-09 2024-08-01 Petmedix Ltd Therapeutic antibodies
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
WO2024165872A1 (en) 2023-02-09 2024-08-15 Petmedix Ltd Therapeutic molecules comprising variants of the extracellular domain of p75 neurotrophin receptor (p75ntr)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
JP3664492B2 (ja) 1994-05-27 2005-06-29 スミスクライン・ビーチャム・ファーマシューティチ・ソシエタ・ペル・アチオニ タチキニン ｎｋ▲下３▼ 受容体アンタゴニストとしてのキノリン誘導体
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
WO1997001352A1 (en) 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1098972B1 (en) 1998-07-22 2010-09-29 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding cdna
SK287323B6 (sk) 1998-11-06 2010-07-07 University Of Z�Rich Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
PT1711530E (pt) * 2003-12-22 2009-10-22 Glaxo Group Ltd Imunoglobulinas neutralizantes de nogo-a para o tratamento de doenças neurológicas
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
EP1786463A4 (en) * 2004-03-26 2009-05-20 Human Genome Sciences Inc ANTIBODY AGAINST NOGO RECEPTOR

Also Published As

Publication number Publication date
ES2389380T3 (es) 2012-10-25
SI1960429T1 (sl) 2012-09-28
AR057239A1 (es) 2007-11-21
JP5015949B2 (ja) 2012-09-05
CN101374863A (zh) 2009-02-25
EP2228391A3 (en) 2010-12-29
AU2006325228B2 (en) 2011-12-15
US20100221260A1 (en) 2010-09-02
HRP20120684T1 (hr) 2012-09-30
EA200801343A1 (ru) 2008-12-30
NZ569143A (en) 2011-08-26
EP1960429B1 (en) 2012-06-27
MA30041B1 (fr) 2008-12-01
CA2633501C (en) 2015-03-31
JO2795B1 (en) 2014-03-15
PT1960429E (pt) 2012-09-25
KR20080080644A (ko) 2008-09-04
PE20071099A1 (es) 2007-11-22
UA96279C2 (uk) 2011-10-25
ZA200805111B (en) 2009-12-30
CR10099A (es) 2008-09-22
GB0525662D0 (en) 2006-01-25
CA2633501A1 (en) 2007-06-21
EP1960429A2 (en) 2008-08-27
JP2009519025A (ja) 2009-05-14
BRPI0619855A2 (pt) 2011-10-25
CN101374863B (zh) 2013-05-29
TW200801038A (en) 2008-01-01
HK1119720A1 (en) 2009-03-13
EP2228391A2 (en) 2010-09-15
EA015536B1 (ru) 2011-08-30
TWI378940B (en) 2012-12-11
WO2007068750A2 (en) 2007-06-21
MY149492A (en) 2013-09-13
PL1960429T3 (pl) 2012-11-30
ZA200906162B (en) 2010-05-26
IL192086A0 (en) 2008-12-29
DK1960429T3 (da) 2012-09-24
WO2007068750A3 (en) 2007-11-29
US8362208B2 (en) 2013-01-29
KR101355118B1 (ko) 2014-02-06
CY1113094T1 (el) 2016-04-13
AU2006325228A1 (en) 2007-06-21
US20130287781A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
NO20082699L (no) Immunoglobuliner
NO20062767L (no) Immunoglobuliner
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20045323L (no) Antistoffer
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
MX2009006891A (es) Anticuerpos cd44.
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TW200709817A (en) Platform antibody compositions
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2006058869A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
NO20076663L (no) Immunoglobuliner
MX2007006357A (es) Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
NO20083045L (no) Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkomplekset
NO20076387L (no) Anvendelse av IL-18BP isoformer til behandling og/eller forhindring av neurologiske inflammatoriske sykdommer
UA87851C2 (uk) Похідні піролотриазину, застосовні для лікування гіперпроліферативних порушень і захворювань, пов'язаних з ангіогенезом
WO2007042543A3 (en) Imidazole derivatives and their use for modulating the gaba-a receptor complex

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application